The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: Updated expert recommendations;Rola systemowych metod leczenia u chorych na niedrobnokomórkowego raka płuca i złośliwego mie{ogonek}dzybłoniaka opłucnej: Uaktualnione zalecenia ekspertów

Pneumonologia i Alergologia Polska

Volumn 82, Issue 2, 2014, Pages 133-149

  Jassem, Jacek ^a   Biernat, Wojciech ^a   Bryl, Maciej ^b   Chorostowska Wynimko, Joanna ^c   Dziadziuszko, Rafał ^a   Krawczyk, Paweł ^d   Kordek, Radzisław ^e   Kowalski, Dariusz M ^f   Krzakowski, Maciej ^f   Olszewski, Włodzimierz ^f   Orłowski, Tadeusz ^c   Ramlau, Rodryg ^b   Rzyman, Witold ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Wielkopolskie Centrum Pulmonologii I Torakochirurgii W Poznaniu   (Poland)

^c Zak ad Fizjopatologii Oddychania im Prof Antoniego Koziorowskiego Instytut Gru licy i Chorób P uc w Warszawie   (Poland)

^d Uniwerystet Medyczny w Lublinie ^*  (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Non small lung cancer treatment; Pleural mesothelioma treatment

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE;

ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; PLEURAL NEOPLASMS; POLAND; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREMEDICATION; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MOLECULAR TARGETED THERAPY; PLEURAL NEOPLASMS; POLAND; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PREMEDICATION; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84897710702     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: 10.5603/PiAP.2014.0019     Document Type: Article

References (156)

1. Wojciechowska U., Didkowska J. Nowotwory złośliwe w Polsce w 2012 ro-ku. Nowotwory J. Oncol. 2013; 63: 197-216.
2. Naruke T., Goya T., Tsuchiya R. i wsp. Prognosis and survival in resected lung carcinoma based on the international staging system. J. Thorac. Cardiovasc. Surg. 1998; 96: 440-447.
3. Jassem J., Skokowski J., Dziadziuszko R. i wsp. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J. Thorac. Cardiovasc. Surg. 2000; 119: 1141-1146.
4. Henschke CI., Yankelevitz DF., Libby DM. i wsp. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 2006; 355: 1763-1771.
5. Jassem J., Drosik K., Dziadziuszko R. i wsp. Zalecenia dotycza{ogonek}ce systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego mie{ogonek}dzybłoniaka opłucnej: Konferencja okra{ogonek}głego stołu. Nowotwory J. Oncol. 2005; 55: 160-166.
6. Jassem J., Drosik K., Dziadziuszko R. i wsp. Systemowe leczenie niedrobnokomórkowego raka płuca i złośliwego mie{ogonek}dzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Nowotwory J. Oncol. 2007; 57: 71-78.
7. Jassem J., Biernat W., Drosik K. i wsp. Uaktualnione zalecenia dotycza{ogonek}ce systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego mie{ogonek}dzybłoniaka opłucnej. Nowotwory J. Oncol. 2010; 60: 51-63
8. Thunnissen E., Kerr KM., Herth FJF. i wsp. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012 76: 1-15.
9. Barlesi F., Pinot D., Legoffic A. i wsp. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br. J. Cancer 2005; 93: 450-452.
10. Camilo R., Capelozzi V.L., Siqueira S.A., Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum. Pathol. 2006; 37: 542-546.
11. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann. Diagn. Pathol. 2004; 8: 259-267.
12. Kalhor N., Zander DS., Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod. Pathol. 2006; 19: 1117-1123.
13. Kargi A., Gurel D., Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl. Immunohistochem. Mol. Morphol. 2007; 15: 415-420.
14. Khayyata S., Yun S., Pasha T. i wsp. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn. Cytopathol. 2009; 37: 178-183.
15. Sturm N., Lantuejoul S., Laverriere MH. i wsp. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum. Pathol. 2001; 32: 918-925.
16. Tan D., Li Q., Deeb G. i wsp. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum. Pathol. 2003; 34: 597-604.
17. Nicholson A.G., Gonzalez D., Shah P. i wsp. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J. Thorac. Oncol. 2010; 5: 436-441.
18. Van Schil PE., Sihoe AD., Travis WD. Pathologic classification of adenocarcinoma of lung. J. Surg. Oncol. 2013; 108: 320-326.
19. Travis WD., Brambilla E., Noguchi M. i wsp. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011; 6: 244-285.
20. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. World Health Organization Classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC; 2004.
21. Yi E.S., Boland J.M., Maleszewski J.J. i wsp. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 2011; 6: 459-465.
22. Paik J.H., Choe G., Kim H. i wsp. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J. Thorac. Oncol. 2011; 6: 466-472.
23. Sholl L.M., Sun H., Butaney M. i wsp. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am. J. Surg. Pathol. 2013; 37: 1441-1449.
24. Stahel R.A., Weder W., Lievens Y. i wsp. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (suppl. 5): v126-128.
25. Butnor K.J., Sporn T.A., Ordonez N.G. Recommendations for the reporting of pleural mesothelioma. Virchows. Arch. 2007; 450: 15-23.
26. Churg A., Colby T.V., Cagle P. i wsp. The separation of benign and malignant mesothelial proliferations. Am. J. Surg. Pathol. 2000; 24: 1183-11200.
27. Rosell R., Gomez-Codina J., Camps C. i wsp. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 1994; 330: 153-158.
28. Roth J.A., Fosella F., Komaki R. i wsp. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst 1994; 86: 673-680.
29. Depierre A., Milleron B., Moro-Sibilot D. i wsp. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J. Clin. Oncol. 2002; 20: 247-253.
30. Gilligan D., Nicolson M., Smith I. i wsp. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929-1937.
31. Pisters K., Vallieres E., Crowley JJ. i wsp. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J. Clin. Oncol. 2010; 28:1843-1849.
32. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. i wsp. Randomized phase III study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in stages IB to IIIA of non-small-cell lung cancer. J. Clin. Oncol. 2012; 30: 172-178.
33. Song W.A., Zhou NK., Wang W. i wsp. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J. Thorac. Oncol. 2010; 5: 510-516.
34. Felip E., Rosell R., Maestre J.A. i wsp. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small cell lung cancer. J. Clin. Oncol. 2010; 28: 3138-3145.
35. Lim E., Harris G., Patel A. i wsp. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison of randomized trials. J. Thorac. Oncol. 2009; 4: 1380-1388.
36. van Meerbeeck J.P., Kramer G.W., Van Schil PE. i wsp. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl. Cancer Inst. 2007; 99: 442-450.
37. Albain K.S., Swann R.S., Rusch V.W. i wsp. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
38. Thomas M., Rübe Ch., Hofknecht P. i wsp. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small cell lung cancer. Lancet. Oncol. 2008; 9: 636-648.
39. Rusch V.W., Giroux D.J., Kraut M.J. i wsp. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J. Clin. Oncol. 2007; 25: 313-318.
40. Kunitoh H., Kato H., Tsuboi M. i wsp. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J. Clin. Oncol. 2008; 26: 644-649.
41. Kappers I., van Sandick J.W., Burgers J.A. i wsp. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur. J. Cardiothorac. Surg. 2009; 36: 741-746.
42. Keller S.M., Adak S., Wagner H. i wsp. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N. Engl. J. Med. 2000; 343: 1217-1222.
43. Waller D., Peake M.D., Stephens R.J. i wsp. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 2004; 26: 173-182.
44. Scagliotti G.V., Fossati R., Torri V. i wsp. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J. Natl. Cancer. Inst 2003; 95: 1453-1461.
45. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 2004; 350: 351-360.
46. Winton T., Livingston R., Johnson D. i wsp. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005; 352: 2589-2597.
47. Strauss GM., Herndon J.E. 2nd., Maddaus MA. i wsp. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J. Clin. Oncol. 2008; 26: 5043-5051.
48. Kato H., Ichinose Y., Ohta M. i wsp. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N. Engl. J. Med. 2004; 350: 1713-1721.
49. Douillard J-Y., Rosell R., De Lena M. i wsp. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006; 7: 719-727.
50. Butts C.A., Ding K., Seymour L. i wsp. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small cell lung cancer: updated survival analysis of JBR-10. J. Clin. Oncol 2010; 28: 29-34.
51. Arriagada R., Dunant A., Pignon J-P. i wsp. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol. 2010; 28: 35-42.
52. Pignon JP., Tribodet H., Scagliotti GV. i wsp. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26: 3552-3559.
53. Arriagada R., Auperin A., Burdett S. i wsp. NSCLC Metaanalyses Collaborative Group. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-smallcell lung cancer: two meta-analyses of individual patient data. Lancet 2010; 375: 1267-1277.
54. Jassem J. Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer. Lancet Oncol. 2001; 2: 335-342.
55. Le Chevalier T., Arriagada R., Quoix E. i wsp. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 1991; 83: 417-423.
56. Dillman R.O., Seagren S.L., Propert K.J. i wsp. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N. Engl. J. Med. 1990; 323: 940-945.
57. Schaake-Koning C., van den Bogaert W., Delasio O i wsp. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992; 326: 524-530.
58. Sause W., Kolesar P., Taylor S. i wsp. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-364.
59. Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995; 76: 593-601.
60. Pritchard R.S., Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A metaanalysis. Ann Intern Med 1996; 125: 723-729.
61. Fournel P., Robinet G., Thomas P. i wsp. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J. Clin. Oncol. 2005; 23: 5910-5917.
62. Furuse K., Fukuoka M., Kawahara M. i wsp. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 1999; 17: 2692-2699.
63. Curran W.J. Jr., Paulus R., Langer C.J. i wsp. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J. Natl. Cancer Inst. 2011; 103: 1452-1460.
64. O'Rourke N., Roqué I Figuls M., Farré Bernadó N., Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 2010; CD002140.
65. Aupérin A., Le Péchoux C., Rolland E. i wsp. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 2010; 28: 2181-2190.
66. De Ruysscher D., Botterweck A., Dirx M. i wsp. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009; 20: 98-102.
67. Bradley J.D., Paulus R., Komaki R. i wsp. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy ± cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617. J. Clin. Oncol. 2013; 15 (suppl): 458s.
68. Machtay M., Hsu C., Komaki R. i wsp. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int. J. Radiat. Oncol. Biol. Phys. 2005; 63: 667-671.
69. Vokes E.E., Herndon J.E., Kelley M.J. i wsp. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J. Clin. Oncol. 2007; 25: 1698-1704.
70. Hanna N.H., Neubauer M., Yiannoutso C. i wsp. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 2008; 26: 5755-5760.
71. Kelly K., Chansky K., Gaspar L. i wsp. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer: SWOG S0023. J. Clin. Oncol. 2008; 26: 2450-2456.
72. Bradley J., Masters GA., Hu C. i wsp. An intergroup randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) chemoradiotherapy (CRT) +/-cetuximab (cetux) for stage III non-small cell lung cancer (NSCLC): Results on cetux from RTOG 0617. IASLC 15th World Conference on Lung Cancer, Sydney 2013, abstr. PL03.05.
73. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 2008; 26: 4617-4625.
74. Socinski M.A., Cromwell R., Hensing T.E. Treatment of non-small-cell lung cancer, stage IV. Chest 2007; 132 (supl): 277-289.
75. Baggstrom M.Q., Stinchcombe T.E., Fried D.B. i wsp. Thirdgeneration chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J. Thorac. Oncol. 2007; 2: 845-853.
76. Goffin J., Lacchetti Ch., Ellis P.M. i wsp. First line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. J. Thorac. Oncol. 2010; 5: 260-274.
77. Delbaldo C., Michelis S., Syz N. i wsp. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-484.
78. Alberola V., Camps C., Provencio M. i wsp. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J. Clin. Oncol. 2003; 21: 3207-3213.
79. Hatem A.A., Elttar I., Loberizo Jr F.R. i wsp. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer 2009; 64: 194-198.
80. Boni C., Tiseo M., Boni L. i wsp. Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial. Br. J. Cancer 2012; 106: 658-665.
81. Ardizzoni A., Boni L., Tiseo M. i wsp. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst. 2007; 99: 847-857.
82. Kelly K., Crowley J., Bunn P.A. Jr. i wsp. Randomized phase III trial of paclitaxel plus carboplatin vs vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J. Clin. Oncol. 2001; 19: 3210-3218.
83. Schiller J.H., Harrington D., Belani CP. i wsp. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 2002; 346: 92-98.
84. Greco AF., Gray., JR., Thompson DS. i wsp. Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma. Cancer 2002; 95: 1279-1285.
85. Gao G., Jiang J., Liang X. i wsp. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009; 65: 339-344.
86. Scagliotti G.V., Parikh P., von Pawel J. i wsp. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 3543-3551.
87. Treat J., Scagliotti GV., Peng G. i wsp. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials. Lung Cancer 2012; 76: 222-227.
88. Park JO., Kim SW., Ahn JS. i wsp. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 2007; 25: 5233-5239.
89. von Plessen C., Bergman B., Andresen O. i wsp. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br. J. Cancer 2006; 95: 966-573.
90. Socinski M.A., Schell M.J., Peterman A i wsp. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second line therapy in advanced stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol. 2002; 20: 1335-1343.
91. Smith I.E., O'Brien MER., Talbot D.C. i wsp. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three vs six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. 2001; 19: 1336-1343.
92. Soon Y.Y., Stockler M.R., Askie L.M., Boyer M.J. Duration of chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis of randomized trials. J. Clin. Oncol. 2009; 20: 3277-3284.
93. Brodowicz T., Krzakowski M., Zwitter M. i wsp. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-163.
94. Ciuleanu T., Brodowicz T., Zielinski C. i wsp. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
95. Paz-Ares L.G., de Marinis F., Dediu M. i wsp. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2013; 31: 2895-2904.
96. Guetz G., Uzzan B., Nicolas P. i wsp. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. Crit. Rev. Oncol. Hematol. 2012; 84: 340-349.
97. Quoix E., Zalcman G., Oster JP. i wsp. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079-1088.
98. Frasci G., Lorusso V., Panza N. i wsp. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 2529-2536.
99. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl. Cancer Inst 1999; 91: 66-72.
100. Hainsworth J.D., Spigel D.R., Farley C. i wsp. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110: 2027-2034.
101. Lilenbaum R.C., Herndon J. E 2nd., List MA. i wsp. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730). J. Clin. Oncol. 2005; 23: 190-196.
102. Zukin M., Barrios C.H., Pereira JR., i wsp. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J. Clin. Oncol. 2013; 31: 2849-2853.
103. Barlesi F., Jacot W., Astoul P., Pujol J-L. Second-line treatment for advanced non-small-cell lung cancer: a systematic review. Lung Cancer 2006; 51: 159-172.
104. Di Maio M., Chiodini P., Georgoulias V. i wsp. Meta-analysis of single agent chemotherapy compared with combination chemotherapy as a second-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2009; 27: 1836-1843.
105. Petrelli F., Coinu A., Cabiddu M. i wsp. Platinum rechallenge in patients with advanced NSCLC; A pooled analysis. Lung Cancer 2013; 81: 337-342.
106. Shepherd FA., Dancey J., Ramlau R. i wsp. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000; 18: 2095-2103.
107. Fossella F.V., DeVore R., Kerr R.N. i wsp. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 2000; 18: 2354-2362.
108. Hanna N., Shepherd FA., Fossella FV. i wsp. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-1597.
109. Peterson P., Park K., Fossella F. i wsp. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer. J. Thorac. Oncol. 2007; 2: S851 (abstr.).
110. Scagliotti G., Brodowicz T., Shepherd F.A. i wsp. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 2011; 6: 64-70.
111. Petrelli F., Borgonovo K., Cabiddu M. i wsp. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer: a meta-analysis of 13 randomised trials. Clinical Lung Cancer 2012; 13: 107-114.
112. Lee C.K., Brown C., Grala R.J. i wsp. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J. Natl. Cancer Inst 2013; 105: 595-605.
113. Rosell R., Carcereny E., Gervais R. i wsp. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13: 239-246.
114. Herbst RS., Prager D., Hermann R. i wsp. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005; 23: 5892-5899.
115. Gatzemeier U., Pluzanska A., Szczesna A i wsp. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007; 25: 1545-1552.
116. Giaccone G., Herbst R.S., Manegold C. i wsp. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 2004; 22: 777-784.
117. Herbst R.S., Giaccone G., Schiller J.H. i wsp. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 2004; 22: 785-794.
118. Mok T.S., Wu Y.L., Thongprasert S. i wsp. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957.
119. Wu Y.L., Zhou C., Hu C.P. i wsp. LUX-Lung 6: A randomized., open-label, phase III study of afatinib (A) versus gemcitabine/ cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung. J. Clin. Oncol. 2013; 31 (suppl): abstr 8016.
120. Sequist L.V., Yang J. C-H., Yamamoto N. i wsp. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 2013; 31: 3327-3334.
121. Shepherd F.A., Pereira R.J., Ciuleanu T. i wsp. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 123-132.
122. Zhu CQ., da Cunha Santos G., Ding K. i wsp. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008; 26: 4268-4275.
123. Thatcher N., Chang A., Parikh P. i wsp. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
124. Kim E.S., Hirsch V., Mok T. i wsp. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
125. Douillard J-Y., Shepherd F.A., Hirsch V. i wsp. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J. Clin. Oncol. 2010; 28: 744-752.
126. Ciuleanu T., Stelmakh L., Cicenas S. i wsp. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012; 13: 300-308.
127. Cappuzzo F., Ciuleanu T., Stelmakh L. i wsp. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010; 11: 521-529.
128. Zhang L., Ma S., Song X. i wsp. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol. 2012; 13: 466-575.
129. Johnson B.E., Kabbinavar F., Fahrenbacher L. i wsp. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Clin. Oncol. 2013; 31: 3926-3934.
130. Pirker R., Pereira JR., Szczesna A. i wsp. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
131. Lynch T.J., Patel T., Dreisbach L. i wsp. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-smallcell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 2010; 28: 911-917.
132. Kwak E., Bang Y.J., Camidge R. i wsp. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363: 1693-1703.
133. Shaw AT., Yeap BY., Solomon BJ. i wsp. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol. 2011; 12: 1004-1012.
134. Shaw AT., Kim DW., Nakagawa K., i wsp. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013; 368: 2385-2394.
135. Seto T., Kiura K., Nishio M. i wsp. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013; 14: 590-598.
136. Bergethon K., Show A.T., Ou SHI. i wsp. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012; 30: 863-870.
137. Sandler A., Gray R., Perry M.C. i wsp. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006; 355: 2542-2550.
138. Reck M., von Pawel J., Zatloukal P. i wsp. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 2009; 27: 1227-1234.
139. Zinner R., Ross H.J., Weaver R. i wsp. Randomized, open-label phase III study of pemtrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2013; 31 (suppl): abstr. LBA 8003.
140. Socinski A.M., Patel J.D., Garon E.B. i wsp. A phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus bevacizumab (Bev) followed by maintenance pem plus bev versus paclitaxel (Pac) plus cb plus bev followed by maintenance bev in stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC): Overall and age group results. J. Clin. Oncol. 2013; 31 (suppl): abstr. 8004.
141. Barlesi F., Scherpereel A., Rittmeyer A. i wsp. Randomised phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J. Clin. Oncol. 2013; 31: 3004-3011.
142. Sanjaykumar H., Chu D., Shenhong W. Risk of gastrointestinal perforation in patients with cancer treaded with bevacizumab: a metaanalysis. Lancet Oncol. 2009; 10: 559-568.
143. Nalluri S.R., Chu D., Keresztes R. i wsp. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients. JAMA 2008; 300: 2277-2285.
144. Soria J.C., Mauguen A., Reck M. i wsp. Systematic review and meta-analysis of randomised., phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013; 24: 20-30.
145. Mellemgaard A., Kaiser R., Douillard J.Y. i wsp. Analysis of overall survival in adenocarcinoma NSCLC patients receiving 2nd line combination treatment with nintedanib (BIBF 1120) + docetaxel in the LUME-Lung 1 trial: A randomized, double-blind, placebo-controlled phase 3 study. Eur. J. Cancer 2013; 49 (suppl 2): abstr. 3409.
146. Butts C.A., Socinski MA., Mitchell P. i wsp. START: a phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. J. Clin. Oncol. 2013; 31 (suppl): abstr. 7500.
147. Ellis P., Davies AM., Evans WK. i wsp. The use of chemotherapy In patients with advanced malignant pleural mesothelioma: a systematic review and practice guidelines. J. Thorac. Oncol. 2006; 1: 591-601.
148. Muers M.F., Stephens R.J., Fisher P. i wsp. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694.
149. Vogelzang NJ., Rusthoven JJ., Symanowski J. i wsp. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636-2644.
150. Symanowski J., Rushoven J., Nguyen B. i wsp. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2003; 22: 647.
151. Jassem J., Ramlau R., Santoro A. i wsp. Pemetrexed plus best supportive care versus best supportive care in previously treated patients with advanced malignant pleural mesothelioma: A randomized phase III trial. J. Clin. Oncol. 2008; 26: 1698-1704.
152. Zucali PA., Simonelli M., Michetti G. i wsp. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012; 75: 360-367.
153. Weder W., Stahel R.A., Bernhard J. i wsp. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202.
154. De Perrot M., Feld R., Cho B. i wsp. Trimodality therapy with induction chemotherapy followed bu extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 2009; 27: 1413-1418.
155. Krug L., Pass H., Rusch V. i wsp. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 2009; 27: 3007-3013.
156. Bokulbas S., Manegold C., Eberlein M. i wsp. Survival after trimodality therapy for malignant pleural mesothelioma: Radical pleurectomy., chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011; 71: 75-81.